A detailed history of Marshall Wace, LLP transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 1,405,714 shares of RLAY stock, worth $6.28 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,405,714
Previous 276,702 408.02%
Holding current value
$6.28 Million
Previous $1.8 Million 451.66%
% of portfolio
0.01%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.23 - $9.51 $7.03 Million - $10.7 Million
1,129,012 Added 408.02%
1,405,714 $9.95 Million
Q2 2024

Aug 14, 2024

BUY
$5.9 - $8.02 $1.63 Million - $2.22 Million
276,702 New
276,702 $1.8 Million
Q1 2022

May 16, 2022

SELL
$20.26 - $32.36 $50,629 - $80,867
-2,499 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$26.0 - $37.03 $448,006 - $638,063
-17,231 Reduced 87.33%
2,499 $77,000
Q3 2021

Nov 15, 2021

SELL
$29.75 - $37.99 $2.06 Million - $2.63 Million
-69,101 Reduced 77.79%
19,730 $622,000
Q2 2021

Aug 13, 2021

BUY
$27.5 - $38.19 $2.17 Million - $3.01 Million
78,729 Added 779.34%
88,831 $3.25 Million
Q1 2021

May 17, 2021

BUY
$32.52 - $61.53 $328,517 - $621,576
10,102 New
10,102 $349,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $537M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.